Aurobac Therapeutics

Latest News

13 February 2023

AUROBAC THERAPEUTICS announces appointment of Martin Everett as Chief Scientific Officer

Commenting on the appointment, AUROBAC THERAPEUTICS CEO Florence Séjourné: “I am delighted that Martin is joining us. His incredibly strong knowledge and experience will be instrumental in helping us achieve our ambitious goals and making a profound impact in the field of antimicrobial resistance.”

Know more

4 October 2022

AUROBAC THERAPEUTICS appoints Florence Séjourné as Chief Executive Officer

“Florence’s is an experienced biotech leader with outstanding strategic and operational acumen. The Board has great confidence in her to successfully set-up and lead AUROBAC.” said Frank Kalkbrenner, Ph.D., Co-Founder and Chairman of the Board of AUROBAC.

Know more

6 July 2022

Boehringer Ingelheim, Evotec and bioMérieux launch AUROBAC THERAPEUTICS, a joint venture to fight AntiMicrobial Resistance

The resulting company, AUROBAC THERAPEUTICS SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.

Know more

Aurobac Therapeutics

STAY CONNECTED

Register to our newsletter and/or Stay informed of our latest news

CONTACT US

AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance

This website is a temporary version; a complete new website will be available in 2023!

Legal Notice